• 1. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 4. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 5. An integrated digital microfluidic chip for multiplexed proteomic sample preparation and analysis by MALDI-MS?
  Hyejin Moon,Aaron R. Wheeler,Robin L. Garrell,Chang-Jin “CJ” Kim Lab Chip, 2006,6, 1213-1219

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Lactones Delta valerolactones

Professional Introduction to 3β-HYDROXY SIMVASTATIN (CAS No. 126313-98-2)

3β-HYDROXY SIMVASTATIN, identified by the Chemical Abstracts Service Number (CAS No.) 126313-98-2, is a significant intermediate in the synthesis of simvastatin, one of the most widely prescribed statins for the management of hypercholesterolemia. This compound plays a pivotal role in pharmaceutical chemistry due to its structural relationship with simvastatin, a drug that has been extensively studied for its efficacy in lowering low-density lipoprotein (LDL) cholesterol levels. The synthesis and pharmacological properties of 3β-hydroxy simvastatin have been subjects of considerable research interest, particularly in understanding the mechanisms of cholesterol reduction and potential therapeutic applications.

The chemical structure of 3β-hydroxy simvastatin consists of a lactone ring, a feature that is characteristic of many natural statins derived from fungal metabolites. Specifically, it is derived from *Aspergillus terreus*, where it serves as a precursor in the enzymatic and chemical transformations leading to the final active pharmaceutical ingredient (API), simvastatin. The hydroxyl group at the 3β position is crucial for the biological activity of the compound, influencing both its solubility and interactions with metabolic enzymes such as HMG-CoA reductase, which is the primary target of statins.

In recent years, research on 3β-hydroxy simvastatin has expanded beyond its role as a synthetic intermediate. Studies have begun to explore its potential direct therapeutic effects, particularly in contexts where simvastatin may not be optimal due to side effect profiles or drug-drug interactions. For instance, preclinical studies have suggested that 3β-hydroxy simvastatin may possess anti-inflammatory properties in addition to its cholesterol-lowering effects. This dual functionality is particularly intriguing because inflammation is increasingly recognized as a key component in the pathogenesis of cardiovascular diseases alongside hypercholesterolemia.

The pharmacokinetic profile of 3β-hydroxy simvastatin has also been a focus of investigation. Unlike simvastatin, which undergoes extensive metabolism before reaching therapeutic levels in the bloodstream, 3β-hydroxy simvastatin exhibits higher bioavailability in certain models. This observation has led researchers to hypothesize that it might offer a more efficient route to therapeutic concentrations, potentially reducing the required dosage and associated side effects. Furthermore, its stability under various physiological conditions makes it an attractive candidate for formulation into novel drug delivery systems, such as sustained-release formulations or targeted nanoparticles.

Advances in computational chemistry and molecular modeling have further enhanced our understanding of 3β-hydroxy simvastatin's interactions with biological targets. These tools have allowed researchers to predict how modifications to its structure could enhance its efficacy or reduce toxicity. For example, studies using virtual screening have identified derivatives of 3β-hydroxy simvastatin that may exhibit improved binding affinity for HMG-CoA reductase while maintaining a favorable safety profile. Such findings are particularly relevant in the context of developing next-generation statins that address current limitations.

The role of 3β-hydroxy simvastatin in drug development extends beyond cardiovascular applications. Emerging evidence suggests that it may have neuroprotective effects, making it a candidate for investigating potential treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The ability of statins to cross the blood-brain barrier and modulate inflammatory pathways within the central nervous system has opened new avenues for research into 3β-hydroxy simvastatin's broader therapeutic utility.

In industrial settings, the production of 3β-hydroxy simvastatin has been optimized through continuous flow chemistry techniques, which improve yield and reduce waste compared to traditional batch processing methods. These innovations align with global trends toward greener pharmaceutical manufacturing practices. Additionally, biocatalytic approaches using engineered enzymes have shown promise in converting precursor molecules into 3β-hydroxy simvastatin with high selectivity and minimal byproducts, further enhancing sustainability.

The regulatory landscape for compounds like 3β-hydroxy simvastatin continues to evolve as new scientific data emerges. Regulatory agencies now often require comprehensive toxicological assessments before approving new drug candidates or intermediates. Fortunately, existing data on statins provides a strong foundation for evaluating the safety profile of 3β-hydroxy simvastatin, though long-term studies are still needed to fully characterize its risks and benefits.

Future research directions for 3β-hydroxy simvastatin include exploring its potential role in combination therapies with other lipid-modifying agents or anti-inflammatory drugs. Such combinations could address multiple aspects of cardiovascular risk simultaneously, offering more holistic treatment strategies. Furthermore, investigating its mechanism of action at a molecular level may uncover novel pathways relevant to metabolic disorders beyond hypercholesterolemia.

In conclusion,3β-HYDROXY SIMVASTATIN (CAS No. 126313-98-2) represents more than just an intermediate in pharmaceutical synthesis; it is a compound with significant untapped potential for therapeutic applications across multiple disease areas. Its unique structural features, combined with emerging research findings, position it as a promising candidate for further exploration in both academic and industrial settings.

• 134523-09-4(Butanoic acid,2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3-hydroxy-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenylester)
• 130468-11-0(6-Oxo Simvastatin)
• 145576-25-6(4'-Acetyl Simvastatin)
• 121624-18-8(6’-Exomethylene Simvastatin)
• 75330-75-5(Lovastatin)
• 79902-63-9(Simvastatin)
• 73573-88-3(Mevastatin)
• 81093-37-0(Pravastatin)
• 121009-77-6(1-Naphthaleneheptanoicacid, 8-(2,2-dimethyl-1-oxobutoxy)-1,2,6,7,8,8a-hexahydro-b,d-dihydroxy-2,6-dimethyl-, (bR,dR,1S,2S,6R,8S,8aR)-)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)